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Background: Data from seven recent randomized clinical trials have 
demonstrated that epidermal growth factor (EGFR) mutation status 
is predictive of improved progression-free survival and quality of 
life from first-line EGFR tyrosine kinase inhibitor therapy compared 
with platinum-based chemotherapy. We examined barriers to the ini-
tial implementation of a national EGFR testing policy in Canada.
Methods: Five laboratories across Canada underwent a validation and 
quality-control exercise for EGFR mutation testing using reverse tran-
scriptase–polymerase chain reaction with financial support from the 
pharmaceutical industry for the initial 12 months. Oncologists regis-
tered patients with nonquamous histology for EGFR mutation test-
ing using a Web-based platform. Basic demographics were collected 
including age, histology, sex, smoking status, and ethnicity. The deci-
sion to prescribe gefitinib was subsequently registered on the system.
Results: Between March and December 2010, 2104 requests were 
received for EGFR mutation testing. Demographic details are as 
follows: adenocarcinoma (91.6%); Asian ethnicity (13.9%); female 
(58%); light/never smoker (41.3%); stage IV disease (87.1%). The 
number of tests requested each month ranged from 200 to 250. 
Mutation testing was conducted in 1771 of 2104 requests (84%). 
The median turnaround time for EGFR testing was 18 days (standard 
deviation 9.7). Gefitinib was prescribed in 302 patients (17.1%). The 
number of test requests dropped to 50 to 100 per month at the end of 
the initial 12 months.
Conclusion: There was rapid uptake of EGFR mutation testing into 
routine clinical practice in Canada. Uptake of EGFR mutation testing 
dropped substantially once funding from pharmaceutical industry 
was discontinued. There is a need for a national strategy to ensure 
resources are in place to implement molecular testing for new molec-
ularly targeted agents.
Key Words: Non–small-cell lung cancer, Epidermal growth factor 
mutations, Molecular testing,Implementation.
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Significant advances have taken place in the management of patients with advanced and metastatic non–small-cell 
lung cancer (NSCLC) over the last 5 years. Traditionally, all 
advanced NSCLC patients were treated in a similar manner, 
in which a platinum-based two-drug combination was given 
as first-line therapy,1,2 docetaxel or pemetrexed as second-
line therapy,3,4 and erlotinib as second- or third-line therapy 
for patients who remained well enough for treatment.5 More 
recently, the importance of pathologic subtype has been rec-
ognized. Data from several randomized trials demonstrate that 
pathologic subtype is predictive of improved survival with 
selected systemic therapies.6,7 These changes were rapidly 
incorporated into treatment algorithms.
There have also been major advances in the under-
standing of the molecular pathogenesis of NSCLC, resulting 
in intense research efforts to evaluate molecularly targeted 
agents for defined subsets of patients. Tyrosine kinase inhibi-
tors (TKIs) of the epidermal growth factor receptor (EGFR) 
gene were initially shown to have modest improvements in 
survival in an unselected population of NSCLC patients.5 
Further analysis suggested that clinical characteristics such 
as Asian ethnicity, adenocarcinoma histology, female sex, and 
never-smoking status, were associated with a higher likeli-
hood of response to EGFR TKIs.8 However, the discovery of 
activating mutations of the EGFR gene in 20049,10 identified a 
subgroup of patients who seemed to derive dramatic benefits 
from EGFR TKI therapy.
Historical data suggested that the addition of EGFR TKI 
therapy to patients with EGFR mutation–positive NSCLC 
improved survival.11 Multiple trials have since been con-
ducted comparing EGFR TKIs with platinum-based chemo-
therapy as first-line therapy for advanced/metastatic NSCLC 
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(Table 1).12–18 The initial trials, Iressa Pan Asian Study (IPASS) 
and First Signal,12,16 selected patients based on clinical charac-
teristics associated with a higher probability of harboring an 
EGFR mutation. The IPASS trial demonstrated that patients 
with EGFR mutation–positive NSCLC had significantly lon-
ger progression-free survival (PFS) if they received gefitinib 
compared with carboplatin and paclitaxel chemotherapy 
(hazard ratio 0.48; 95% confidence interval 0.36–0.64; p < 
0.001).16 Of equal importance was the finding that patients 
with EGFR wild-type NSCLC randomized to initial therapy 
with gefitinib had inferior outcomes (PFS hazard ratio 2.85, 
95% confidence interval 2.05–3.98; p < 0.001). Five subse-
quent trials, performed exclusively in EGFR mutation–pos-
itive patients, have all confirmed that EGFR TKI therapy is 
the preferred first-line therapy in this molecularly defined sub-
group of NSCLC patients, with higher response rates, PFS, 
TABLE 1.  Summary of Trials of First-Line Trials of EGFR TKI Versus Chemotherapy
Trial Treatment Population RR PFS (m) PFS (HR) QoL
IPASS16 Gef vs. Cb/Pac Mut+ 71% vs. 47% 0.48 ↑
Mut− 1% vs. 23% 2.85
First Signal12 Gef vs. Cis/Gem Mut+ 85% vs. 37% 0.61 ↑
Mut− 26% vs. 52% 1.52
NEJ00213 Gef vs. Cb/pac Mut+ 74% vs. 31% 10.8 vs. 5.4 m 0.30
WJTOG 340515 Gef vs. Cb/Doc Mut+ 62% vs. 32% 9.2 vs. 6.3 m 0.49
Optimal18 Erl vs. Cb/Gem Mut+ 83% vs. 36% 13.1 vs. 4.6 m 0.16
EURTAC17 Erl vs. plt doub Mut+ 58% vs. 15% 9.7 vs. 5.2 m 0.37 Not reported
Lux Lung 314 Afat vs. Cis/Pem Mut+ 56% vs. 23% 11.1 m vs. 6.9 m 0.58 ↑
↑QoL better for EGFR TKI.
Gef, gefitinib; Erl, erlotinib; Cb, carboplatin; Cis, cisplatin; Pac, paclitaxel; Gem, gemcitabine; Doc, docetaxel; Afat, afatanib; 
Pem, pemetrexed; mut, mutation; plat doub, platinum doublet; PFS, progression-free survival; QoL, quality of life; HR, hazard ratio; 
RR, reponse rate.
FIGURE 1. A, Initial uptake of EGFR 
mutation testing (March–December 
2010). B, Number of EGFR-mutation 
tests performed upon completion of 
sponsored program (April–September 
2011). EGFR, epidermal growth factor 
receptor.
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and improved symptom control and/or quality of life.13–15,17,18 
Because of high rates of treatment crossover in these trials, 
survival differences were not seen.
The findings from these trials gained broad acceptance 
among oncologists worldwide. International and Canadian 
consensus recommendations,19–21 as well as an Ontario Health 
Technology Assessment Committee report22 recommended 
that tumor samples from patients with advanced/metastatic 
NSCLC should be tested for the presence of an activating 
mutation of the EGFR. Although gefitinib received Health 
Canada approval for the first-line treatment of advanced EGFR 
mutation–positive NSCLC in 2009, there was no mechanism 
in place in Canada to perform EGFR mutation testing in clini-
cal laboratories. A national network of laboratories was set 
up across Canada, with funding support from AstraZeneca 
Canada, to perform EGFR mutation testing.23 This was linked 
to compassionate supply of gefitinib for those patients with 
EGFR mutation–positive tumors. This article reports on the 
uptake of EGFR testing in Canada.
PATIENTS AND METHODS
The Canadian health care system is publicly funded 
through each province or territory. EGFR mutation testing was 
not available in Canada outside of research laboratories before 
March 2010. Five laboratories across the country undertook 
validation and quality-control processes to establish a net-
work for EGFR mutation testing using reverse transcriptase–
polymerase chain reaction (British Columbia Cancer Agency 
[BC], Alberta Cancer Agency, University Health Network, 
Centre de Lutte Contre le Cancer du CHUM Quebec, and 
Jewish General Hospital Quebec ).23 Laboratories were 
reimbursed for testing by AstraZeneca Canada for an initial 
12 months.
Patients were eligible for EGFR mutation testing if they 
had advanced/metastatic NSCLC and nonsquamous histology. 
Requests for testing were made through an electronic Web-
based platform. Information was collected on age, histology, 
sex, smoking status, and ethnicity, in addition to specimen 
location and identification number. A request was sent to the 
original reporting pathology laboratory to forward tumor sam-
ples (blocks or slides) to one of the five validated laboratories 
for EGFR mutation testing. Results were forwarded directly 
from the testing laboratory to the requesting physician, as well 
as the initial reporting laboratory. Subsequently, the decision 
to prescribe gefitinib for EGFR mutation positive patients 
was entered into the system. From March 2010 until March 
2011, gefitinib was provided free of charge to EGFR muta-
tion–positive patients. Dates of initial test request, receipt of 
sample at the testing laboratory, and completion of the test 
were recorded.
Data in this report were collected from the initial 10 
months of the EGFR testing program (March–December 
2010). Additional data on the number of tests performed up 
until 6 months after completion of the funded program are 
also available. The analysis was descriptive, and summary 
information is provided in this report. Testing turnaround 
times were calculated from the recorded dates. The number 
of EGFR mutation–positive tests was not accessible, but was 
inferred from the number of patients for whom gefitinib was 
prescribed. Patients with inadequate tissue for testing were not 
included when calculating the proportion of patients with an 
EGFR mutation.
RESULTS
Approximately 22,000 new lung cancer cases were 
diagnosed in Canada in 2010.24 Assuming 85% of cases were 
NSCLCs, 40% had metastatic disease at diagnosis and 75% 
had nonsquamous histology, then approximately 5600 patients 
were potentially eligible for EGFR mutation testing during 
2010. There was rapid uptake of EGFR testing across Canada 
(Fig. 1A). Between March and December 2010, 2104 requests 
were received for EGFR mutation testing. Demographic infor-
mation is summarized in Table 2. The proportion of light-/
never-smokers (41.3%), women (58%), and Asian ethnicity 
(14%) suggests that Canadian physicians did incorporate clin-
ical characteristics when selecting patients for testing.
EGFR mutation testing was not conducted in 251 
patients (12%) because specimens were not sent to the test-
ing laboratory (n = 106; 5%), or samples were deemed inad-
equate by the testing laboratory (n = 145; 7%). At the time 
of data cutoff, test results were pending for an additional 82 
samples (4%). The median time to transport the sample to the 
testing laboratory was 7 days (standard deviation [SD] 9.6). 
TABLE 2.  Summary of Patient Demographics
Patient Demographics N Proportion (%)
Age (yr)
  <49 135 6.5%
  50–59 379 19.8%
  60–69 573 27.2%
  70–79 712 33.8%
  ≥80 303 14.5%
Sex
  Female 1221 58%
  Male 883 42%
Smoking status
  Light/never 868 41.3%
  Current/former 1236 58.7%
Histology
  Adenocarcinoma 1927 91.6%
  Nonadenocarcinoma 177 8.4%
Ethnicity
  Asian 292 14%
  Non-Asian 1812 86%
Laboratory
  BC 410 19.5%
  AB 178 8.5%
  ON 1239 58.9%
  QC-CHUM 95 4.5%
  QC-Jewish General 182 8.7%
BC, British Columbia Cancer Agency; AB, Alberta Cancer Agency; ON, University 
Health Network; CHUM QC, Centre de Lutte Contre le Cancer du CHUM Quebec; JGH 
QC, Jewish General Hospital Quebec.
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In the initial experience, the median time to perform EGFR 
mutation testing at the test laboratory was 11 days (SD 5.5). 
Overall, the median turnaround time from initial request to 
EGFR result was 18 days (SD 9.7). Across the five labora-
tories, this ranged from 15 to 26 days. Three hundred two 
of 1771 samples (17.1%) tested positive for a mutation. The 
highest mutation-positive rates were seen in patients of Asian 
ethnicity and light-/never-smokers (Fig. 2). There was some 
variation in the rate of EGFR-positive test results across the 
provinces, with the highest rates observed in BC (Fig. 3). This 
likely reflects variation in ethnicity among the provinces.
At the end of 12 months, when the EGFR mutation 
testing and associated compassionate gefitinib program sup-
ported by AstraZeneca were completed, there was a substan-
tial drop in the number of EGFR test requests (Table 3). Over 
the next 6 months, the number of tests performed monthly 
ranged from 50 to 120 (Fig. 1B) in comparison to 200 to 250 
tests per month in the first 12 months.
DISCUSSION
The management of NSCLC has undergone substan-
tial changes in the past few years. The idea that one approach 
can be used to treat all NSCLC patients is no longer valid. 
Chemotherapy algorithms are now dependent on histologic 
subtype. There is increasing recognition that there are distinct 
molecular phenotypes of lung adenocarcinomas.25 To date, 
identification of mutations of the EGFR gene and transloca-
tions of the anaplastic lymphoma kinase gene have resulted in 
specific therapies targeting these molecular abnormalities.16,26 
Identification of other molecular phenotypes, such as KRAS 
mutations27 and ROS1 translocations,28 are also important 
in identifying patient eligibility for ongoing clinical trials. 
However, challenges exist in the ability to test for and identify 
these molecularly defined subsets of NSCLC.
FIGURE 2.  Frequency of epider-
mal growth factor receptor muta-
tions in clinical subgroups. Adeno, 
adenocarcinoma.
FIGURE 3.  Variation across provinces in rate of positive 
epidermal growth factor receptor mutation tests. AB, Alberta 
Cancer Agency; BC, British Columbia Cancer Agency; ON, 
University Health Network Ontario; QC CHUM, Centre de 
Lutte Contre le Cancer du CHUM Quebec; QC JGH, Quebec 
Jewish General Hospital.
TABLE 3.  Summary of Number of EGFR Mutation Tests 
Ordered Per Month, Broken Down by Province
Date EGFR Test Lab
AB BC CHUM JGH ON Total
2010
March 8 27 0 0 34 69
April 10 40 5 13 88 156
May 10 50 6 16 150 235
June 22 44 5 21 152 232
July 20 38 9 20 119 206
August 32 44 14 18 135 233
September 18 36 20 22 132 228
October 16 48 12 30 134 240
November 16 40 14 21 170 261
December 26 43 10 21 135 235
2011
January 27 45 13 18 136 239
February 14 45 5 20 138 222
March 14 37 5 20 122 198
April 0 32 3 11 47 93
May 3 49 0 18 54 124
June 2 43 2 21 36 104
July 0 20 1 15 35 71
August 0 2 1 29 47 79
September 0 0 6 20 48 74
AB, Alberta Cancer Agency; BC, British Columbia Cancer Agency; CHUM QC, 
Centre de Lutte Contre le Cancer du CHUM Quebec; JGH, Jewish General Hospital QC; 
ON, University Health Network Ontario.
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The results presented in this article suggest that 
medical oncologists in Canada rapidly adopted these new 
data into clinical practice. The number of EGFR mutations 
tests ordered rose rapidly in the initial 2 months of testing 
and reached a plateau around 200 to 250 cases per month. 
However, the patient demographics from this report, sug-
gest that physicians were using clinical characteristics, 
such as Asian ethnicity, smoking status, and sex, to select 
patients for whom EGFR mutation testing was to ordered. 
Although this strategy increases the yield for testing, it 
inevitably results in some mutation-positive patients being 
missed. Given the strong predictive value of EGFR muta-
tion results, EGFR mutation testing should be considered in 
all patients with advanced nonsquamous NSCLC with ade-
quate performance status (Eastern Cooperative Oncology 
Group 0–3).
The knowledge translation literature suggests that pas-
sive knowledge translation strategies such as meeting pre-
sentations and publications are not particularly effective in 
changing physician behavior.29 However, these findings would 
suggest that the major limitations to the adoption of EGFR 
mutation testing seem to be access to and reimbursement for 
testing. There was a rapid decline in the number of EGFR 
mutation tests ordered after completion of the sponsored test-
ing and compassionate drug-supply program. The fact that 
there was still no provincial funding mechanism for testing 
or first-line EGFR TKI treatment in place at the end of a year 
indicates that governments need to be more responsive to 
rapidly evolving clinical data if Canadian cancer patients are 
going to have access to new personalized medicines. The cost 
of EGFR mutation testing in Canada is approximately $400 
to $450 per case. On the basis of earlier assumptions to limit 
testing to patients with advanced or metastatic nonsquamous 
NSCLC, this would result in an incremental cost to the health 
care system of $2.2 to $2.52 million. Nevertheless, to approve 
a drug that is only appropriate to a subgroup of NSCLC 
patients, without a mechanism to identify those patients or 
make treatments affordable and accessible to Canadians in the 
context of a publicly funded system is a major impediment to 
adoption of new therapies.
Given the observational nature of this study, there are 
some limitations. There may be other factors contributing to 
these findings. The rate of testing early in the program may 
have been higher if physicians were testing prevalent cases 
rather than just newly diagnosed cases. However, this seems 
less likely given the abrupt drop in the number of tests ordered 
in April 2011. Additionally, data were no longer captured by 
the program in some provinces after the initial 12-month 
period. In Alberta, EGFR mutation testing was supported 
through provincial funds after the initial 12 months. Data 
were not captured in BC after July 2011. Funding for muta-
tion testing was still coming from the pharmaceutical industry 
in several provinces in 2013. These changes likely impact on 
the lower rates of testing observed in August and September 
of 2011, although drug access almost certainly also plays a 
key role.
Multiple challenges exist in implementing EGFR muta-
tion testing (Table 4). Although uptake of EGFR testing was 
high, there were still a significant number of patients not able 
to access testing. There were some barriers to adoption of test-
ing. The limited number of testing laboratories meant that tis-
sue needed to be sent between laboratories for the majority of 
patients. Eligibility for testing was often not determined until 
patients were seen by a medical oncologist. This factor, in com-
bination with the median time to obtain test results of nearly 3 
weeks, limited the feasibility of testing for patients who were 
already symptomatic and could not wait 2 to 3 weeks to begin 
systemic therapy. Many of these patients could not wait for 
test results and needed to start urgent chemotherapy instead 
of receiving personalized cancer therapy. Expansion of the 
number of testing laboratories and allowing for testing to be 
initiated by pathologists at the time of diagnosis would help 
improve access to testing for Canadian lung cancer patients. 
In addition, EGFR testing could not proceed in approximately 
12% of cases because of inadequate tissue samples. This high-
lights the need to obtain appropriate tissue samples to provide 
adequate amounts of tissue for molecular testing at diagnosis. 
Molecular testing is an issue for the majority of disease sites 
in oncology. Coordinated approaches that link reimbursement 
of molecular testing with approval of clinically important 
molecularly targeted agents seems essential to allow adoption 
of new and novel therapies for oncology patients.
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